Amsterdam 2013 Programme Satellite Meetings Registration Exhibition Virtual Exhibition Hotels Visa Letter Invitation
Search Abstracts by author or title
(results will display both Free Papers & Poster)

Creation of a femtosecond laser-assisted new mini-flap to enhance late regression after LASIK

Poster Details

First Author: M.Garcia-Gonzalez SPAIN

Co Author(s):    M. Iglesias Iglesias   J. Sanchez Pina   C. Gimenez Vallejo        

Abstract Details



Purpose:

To describe a method of laser in situ keratomileusis (LASIK) enhancement in which a new femtosecond (FS) laser-assisted mini-flap is created over the original LASIK flap.

Setting:

Vissum Corporación Oftalmológica Santa Hortensia, Madrid, Spain

Methods:

The 60-kHz IntraLase FS laser (IntraLase Corp.) was used to create a new mini-flap over an original LASIK flap for the retreatment of late regression after LASIK. The preferred diameter of the mini-flap is usually 7 mm and the attempted flap depth is 100 ṁm. The purpose of the “mini-flap” is to be smaller and thinner than the original LASIK flap, so the ablation can be performed over the deepest lamellae of the original flap, and not over the original stromal bed, thus decreasing the risk of excessive stromal thinning and postoperative ectasia.

Results:

We performed this procedure on fourteen eyes of ten patients. No intraoperative or postoperative complications developed in any case during the follow-up. At the 6-month follow-up visit, all eyes were within ±0.5 diopters of the targeted refraction.

Conclusions:

Our preliminary results suggested that creation of a FS laser-assisted new mini-flap over a previous LASIK flap seems to be a safe and effective procedure for the enhancement of late regression after LASIK. By creating a FS laser-assisted mini-flap that is smaller in diameter than the original flap, the adhesion of the primary flap edges and peripheral interface remain intact, thus decreasing the risk of dislocation of the original LASIK flap and the risk of losing a sliver of tissue.

Financial Disclosure:

NONE

Back to previous